On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2

@article{Mathiesen2006OnTM,
  title={On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2},
  author={J. Mathiesen and A. Christopoulos and T. Ulven and J. F. Royer and M. Campillo and A. Heinemann and L. Pardo and E. Kostenis},
  journal={Molecular Pharmacology},
  year={2006},
  volume={69},
  pages={1441 - 1453}
}
  • J. Mathiesen, A. Christopoulos, +5 authors E. Kostenis
  • Published 2006
  • Chemistry, Medicine
  • Molecular Pharmacology
    • Chemoattractant receptor-homologous molecule expressed on T helper 2 cells (CRTH2) has attracted interest as a potential therapeutic target in inflammatory diseases. Ramatroban, a thromboxane A2 receptor antagonist with clinical efficacy in allergic rhinitis, was recently found to also display potent CRTH2 antagonistic activity. Here, we present the pharmacological profile of three ramatroban analogs that differ chemically from ramatroban by either a single additional methyl group (TM30642), or… CONTINUE READING
    View on ASPET
    molpharm.aspetjournals.org
    43 Citations
    Highly Influencial Citations
    4
    Background Citations
    16
    Methods Citations
    3
    43 Citations
    Citation Type

    Citation Type

    Pharmacological characterization of CRTh2 antagonist LAS191859: Long receptor residence time translates into long-lasting in vivo efficacy.
    • 8
    Same Target, Different Therapeutic Outcome: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.
    • 3
    Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation
    • 113
    • PDF
    Structures of the Human PGD2 Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition.
    • 18
    • Highly Influenced
    Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy
    • 33
    • PDF
    Trapping of a Nonpeptide Ligand by the Extracellular Domains of the Gonadotropin-Releasing Hormone Receptor Results in Insurmountable Antagonism
    • 13
    • PDF
    Fevipiprant ( QAW 039 ) , a Slowly Dissociating CRTh 2 Antagonist with the Potential for Improved Clinical Efficacy s
    • PDF
    Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
    • 22
    Prostanoid receptor antagonists: development strategies and therapeutic applications
    • 137
    • Highly Influenced
    In vivo studies validating multitargeting of prostanoid receptors for achieving superior anti‐inflammatory effects
    • D. Woodward, J. Wang, +4 authors N. Poloso
    • Biology, Medicine
    • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
    • 2017
    • 3

    References

    SHOWING 1-10 OF 43 REFERENCES
    Identification of Determinants of Ligand Binding Affinity and Selectivity in the Prostaglandin D2 Receptor CRTH2*
    • 30
    • PDF
    An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in Vitro
    • 135
    • PDF
    Pharmacological characterization of the human P2Y13 receptor.
    • 200
    • PDF
    Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2
    • 94
    • PDF
    Inhibitory Effect of the 4-Aminotetrahydroquinoline Derivatives, Selective Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cell Antagonists, on Eosinophil Migration Induced by Prostaglandin D2
    • 24
    • PDF
    Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
    • 85
    15R-Methyl-Prostaglandin D2 Is a Potent and Selective CRTH2/DP2 Receptor Agonist in Human Eosinophils
    • 68
    • PDF
    Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist.
    • 74
    The assessment of antagonist potency under conditions of transient response kinetics.
    • 59
    Antagonist interaction with endogenous AT(1) receptors in human cell lines.
    • 11